Rebalancing TGF-β/Smad7 signaling via Compound kushen injection in hepatic stellate cells protects against liver fibrosis and hepatocarcinogenesis.
Yang YangMayu SunWeida LiChaobao LiuZheshun JiangPengfei GuJingquan LiWei WangRongli YouQian BaXiaoguang LiHui WangPublished in: Clinical and translational medicine (2022)
Our results unveil the approach of CKI in rebalancing TGF-β/Smad7 signaling in HSCs to protect against hepatic fibrosis and hepatocarcinogenesis in both preclinical and clinical studies. Our study suggests that CKI can be a candidate for treatment of hepatic fibrosis and related oncogenesis.